PURA - Puration Takes Strategic Step On Eve Of Legal Medical Marijuana In Texas
July 25 2017 - 10:25AM
InvestorsHub NewsWire
Dallas, TX -- July 25,
2017 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) announced last Thursday, July 20th,
the acquisition of a 25-greenhouse grow operation. The State
of Texas legalized medical marijuana in 2015 and the first licenses
are anticipated to be issued in September 2017. Puration
operates a U.S. Patented cannabis extraction
process and is eager to begin growing its own cannabis
strains. While Texas marijuana law continues to evolve,
Puration has a plan to make money with the grow operation in the
meantime. The Company recently announced a $1.2
million sales contract executed in anticipation of the
acquisition closed last week. After market today, the Company
will publish on its website (purationinc.com) an overview of the
plan to realize the first $1.2 million in sales
and expand over the near term to $16 million in
sales from the Company’s recently announced 25-greenhouse
grow operation. Forbes reported that marijuana sales in the
U.S. last year were over $6 billion, and that
marijuana sales in the U.S are anticipated to exceed $20
billion by 2021. Puration management anticipates
sales from the operation acquired last week can grow to well over
$100 million in annual sales as the legalization
process for medical marijuana matures.
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024